GSK Accused Of Ripping Off La. Medicaid Programs

Law360, New York (February 6, 2013, 9:41 PM EST) -- British pharmaceutical giant GlaxoSmithKline PLC was hit with a lawsuit Tuesday by the Louisiana attorney general alleging its off-label promotion of drugs including antidepressants Wellbutrin and Paxil resulted in fraudulent submissions to state Medicaid programs. 

GSK’s alleged off-label marketing of the drugs, which also include asthma drug Advair and seizure medication Lamictal, bilked the state out of “millions of dollars” in health program reimbursements, according to Louisiana Attorney General Buddy Caldwell.

“GSK’s egregious conduct and greed caused fraudulent claims to be submitted to the Louisiana Medicaid...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.